Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

L8668

Sigma-Aldrich

Levetiracetam

≥98% (HPLC), powder, antiepileptic

Sinonimo/i:

(αS)-α-Ethyl-2-oxo-1-pyrrolidineacetamide, 2(S)-(2-oxopyrrolidin-1-yl)butyramide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C8H14N2O2
Numero CAS:
102767-28-2
Peso molecolare:
170.21
Numero MDL:
MFCD03265610
Codice UNSPSC:
12352200
ID PubChem:
329817665
NACRES:
NA.77

product name

Levetiracetam, ≥98% (HPLC)

Saggio

≥98% (HPLC)

Forma fisica

powder

Colore

white

Solubilità

H2O: >5 mg/mL

Ideatore

UCB Inc.

Stringa SMILE

CC[C@H](N1CCCC1=O)C(N)=O

InChI

1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
HPHUVLMMVZITSG-LURJTMIESA-N

Informazioni sul gene

human ... CACNA1B(774) , SV2A(9900)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

Levetiracetam is a member of the pyrrolidone family, which is a second-generation anti-epileptic drug (AED). It acts as a neuroprotective and hyperalgesic drug. Levetiracetam is implicated in cholinergic neurotransmission.

Applicazioni

Levetiracetam has been used as an anti-epileptic drug to study its effects on glucose-mediated death.

Azioni biochim/fisiol

Levetiracetam is a pyrrolidine with antiepileptic activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.

Caratteristiche e vantaggi

This compound was developed by UCB Inc.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

dust mask type N95 (US), Eyeshields, Gloves

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 8

1 of 8

Rufinamide ≥98% (HPLC), powder

Sigma-Aldrich

R8404

Rufinamide

Lamotrigine ≥98%, powder

Sigma-Aldrich

L3791

Lamotrigine

Levetiracetam-D6 solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-031

Levetiracetam-D6 solution

Carbamazepine powder

Sigma-Aldrich

C4024

Carbamazepine

Levetiracetam impurity E European Pharmacopoeia (EP) Reference Standard

Y0001962

Levetiracetam impurity E

Naratriptan hydrochloride ≥98% (HPLC)

Sigma-Aldrich

N1415

Naratriptan hydrochloride

Primidone analytical standard

Supelco

P7295

Primidone

Levetiracetam Related Compound A United States Pharmacopeia (USP) Reference Standard

USP

1359426

Levetiracetam Related Compound A

Shaikhah Alshuaib et al.
Synapse (New York, N.Y.), 74(8), e22154-e22154 (2020-03-20)
Levetiracetam (LEV) is a widely prescribed antiepileptic drug, but its actions on neuronal function are not fully characterized. Since this drug is believed to enter neurons by binding to a vesicular protein during endocytosis, we used motor axons of the
Levetiracetam as an antiepileptic, neuroprotective, and hyperalgesic drug
Cortes-Altamirano JL, et al.
Neurology India, 64(6), 1266-1266 (2016)
Opposing effects of fasting metabolism on tissue tolerance in bacterial and viral inflammation
Wang A, et al.
Cell, 166(6), 1512-1525 (2016)
Hai-Dun Yan et al.
Brain research bulletin, 90, 142-148 (2012-10-31)
Levetiracetam (LEV) is a widely used antiepileptic agent for partial refractory epilepsy in humans. LEV has unique antiepileptic effects in that it does not inhibit electroshock- or pentylenetetrazol-induced convulsion, but does inhibit seizures in kindling animal and spontaneously epileptic rat
Radica M Stepanović-Petrović et al.
Anesthesia and analgesia, 115(6), 1457-1466 (2012-11-13)
We have recently shown that levetiracetam, administered systemically, exerts an antihyperalgesic effect in a rat inflammatory pain model. In this study, we examined whether levetiracetam has local peripheral antihyperalgesic/anti-edematous effects in the same model of localized inflammation and whether opioidergic
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.